Effectiveness of percutaneous transluminal coronary angioplasty in cardiogenic shock during acute myocardial infarction

Seydoux, Charles; Goy, Jean‐Jácques; Beuret, Philippe; Stauffer, Jean‐Christophe; Vogt, Pierre; Schaller, Marie-Denise; Kappenberger, Lukas; Perret, C

doi:10.1016/0002-9149(92)90804-8

Cited by 34 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The improvement in technical success in this subset is consistent with the documented benefits of stents in treating potentially occlusive dissection flaps and of antiplatelet therapies in terms of reducing thromboembolism in the broad range of coronary artery disease patients. The coupling of improved technical success in PCI with improved short‐term survival of cardiogenic shock patients has been observed in 12 separate observational studies, most of which are cited here [12–20] and all of which are listed in a recent review [4]. Additionally, regarding stents and abciximab, these data are consistent with the observations of a number of groups of investigators [29–33].…”

Section: Discussionsupporting

confidence: 73%

“…Cardiogenic shock remains the leading cause of death from acute myocardial infarction (MI), with historic in‐hospital mortalities in the 80–90% range [1–6]. A number of more recent longitudinal studies and trials report lower in‐hospital mortalities and raise optimism about a number of therapeutic alternatives, such as reperfusion with either thrombolytic drugs (lytics) [7–9], percutaneous coronary intervention (PCI) [10–20], or coronary artery bypass graft surgery (CABG) [21–23], with or without intra‐aortic balloon counterpulsation or other means of mechanical support [24–28]. Recent observational studies have supported the addition of stents and the glycoprotein IIb/IIIa inhibitor, abciximab, to the PCI treatment of cardiogenic shock [29–33].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention

Huang

Sacks

Thai

et al. 2005

Cathet Cardio Intervent

View full text Add to dashboard Cite

This retrospective observational review compares patient characteristics and in-hospital and long-term outcomes of cohorts of patients undergoing percutaneous coronary intervention (PCI) for cardiogenic shock complicating acute myocardial infarction (MI) prior to the use of stents (as well as glycoprotein IIb/IIIa inhibitor and dual-antiplatelet therapy) with PCI in the stent era. Cardiogenic shock remains the leading cause of hospital mortality from acute MI. This is a report of consecutive patients with cardiogenic shock complicating acute MI, without mechanical complication, referred for emergency catheterization to a single operator at two consecutive Veterans Affairs medical centers over a 15-year period (1988 to August 2003). PCI was attempted in all 93 cases: 44 consecutive patients in the present era and 49 consecutive patients in the stent era. Patients with comparable extent of coronary disease, more ST elevation myocardial infarction, multiple areas of infarction, and greater comorbidity underwent PCI in the stent era. Nevertheless, PCI in the stent era was associated with higher rates of acute success and improved in-hospital survival. Kaplan-Meier curves and log-rank testing showed highly significant improvement in overall survival (P < 0.0001). Logistic regression of in-hospital survival demonstrated that stent use (colinear with glycoprotein IIb/IIIa use and dual-antiplatelet therapy) was significantly associated with survival in a model adjusting for extent of coronary disease and comorbidities (P = 0.007). Stents and abciximab have been associated with improved acute angiographic and procedural success of PCI for cardiogenic shock, leading to improved survival.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention

Huang

Sacks

Thai

et al. 2005

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Although it remains controversial as to whether intravenous thrombolytic therapy or primary PCI should be recommended as first-line therapy for all patients with STEMI, many studies point to lower in-hospital mortality rates in selected AMI patients with cardiogenic shock treated with PCI vs. thrombolytic therapy (40% vs. 80%, respectively) (41)(42)(43)(44)(45)(46). In a recent Czech study comparing three treatment strategies for patients presenting to community hospital without PCI capability, the composite rate of death, re-infarction and stroke at 30 days was 8% for patients transported for primary PCI without prior thrombolysis, 15% for patients who received thrombolysis en route to catheterization, and 23% for patients who received thrombolysis at the community hospital (47).…”

Section: Discussionmentioning

confidence: 99%

Potential diversion rates associated with prehospital acute myocardial infarction triage strategies

Anderson¹,

Mitchell²,

Rathlev³

et al. 2004

The Journal of Emergency Medicine

View full text Add to dashboard Cite

“…If angioplasty is successful in achieving reperfusion, mortality can be considerably reduced. [53][54][55] The greatest likelihood of success seems to be in younger patients with single vessel disease. [56] Data on effects of aggressive treatment in elderly patients are lacking.…”

Section: Treatment Of Congestive Heart Failurementioning

confidence: 99%

Optimal Treatment After Acute Myocardial Infarction in the Elderly

Herlitz

Hartford

Dellborg³

et al. 1995

Drugs & Aging

View full text Add to dashboard Cite

Elderly patients with acute myocardial infarction (AMI) more often have a previous history of cardiovascular disease than do younger patients. Furthermore, they less frequently present with typical symptoms and a typical electrocardiogram pattern. Whereas age is the most important predictor for mortality after AMI, the relationship between age and morbidity is more complex. Treatment of elderly patients with AMI is very similar to treatment of younger patients. However, the risk of intolerability to various drugs increases with age, and in many instances doses have to be adjusted. In many trials, the number of lives saved with various interventions seem, if anything, to be more numerous among the elderly. However, it should be remembered that experience with various treatments in the elderly (patients aged > 80 years) is limited. Whether experiences with people aged up to 80 years can be extrapolated to higher age groups is debatable. With increasing age, there is an increased frequency of other disabling diseases, as well as generalised atherosclerosis. It might very well be that even in the elderly it is possible to relieve symptoms and improve morbidity, even though the effects on the prognosis are likely to be less marked.

show abstract

Effectiveness of percutaneous transluminal coronary angioplasty in cardiogenic shock during acute myocardial infarction

Cited by 34 publications

References 6 publications

Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention

Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention

Potential diversion rates associated with prehospital acute myocardial infarction triage strategies

Optimal Treatment After Acute Myocardial Infarction in the Elderly

Contact Info

Product

Resources

About